Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm.
Zafar A, Drobni ZD, Lei M, Gongora CA, Quinaglia T, Lou UY, Mosarla R, Murphy SP, Jones-O'Connor M, Mahmood A, Hartmann S, Gilman HK, Weekes CD, Nipp R, Clark JR, Clark JW, Blaszkowsky LS, Tavares E, Neilan TG. Zafar A, et al. Among authors: nipp r. PLoS One. 2022 Apr 7;17(4):e0265767. doi: 10.1371/journal.pone.0265767. eCollection 2022. PLoS One. 2022. PMID: 35390017 Free PMC article.
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia.
Johnson PC, Woyach JA, Ulrich A, Marcotte V, Nipp RD, Lage DE, Nelson AM, Newcomb RA, Rice J, Lavoie MW, Ritchie CS, Bartlett N, Stephens DM, Ding W, Owen C, Stone R, Ruppert AS, Mandrekar SJ, Byrd JC, El-Jawahri A, Le-Rademacher J, Rosko A. Johnson PC, et al. Among authors: nipp rd. J Geriatr Oncol. 2023 Jul;14(6):101538. doi: 10.1016/j.jgo.2023.101538. Epub 2023 Jun 15. J Geriatr Oncol. 2023. PMID: 37329769 Free PMC article.
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, Faris JE, Murphy JE, Nipp R, Fernandez-Del Castillo C, Ferrone CR, Hong TS. Wo JY, et al. Among authors: nipp r. Am J Clin Oncol. 2018 Jul;41(7):656-661. doi: 10.1097/COC.0000000000000349. Am J Clin Oncol. 2018. PMID: 28134673
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR. Michelakos T, et al. Among authors: nipp rd. Ann Surg. 2019 Apr;269(4):733-740. doi: 10.1097/SLA.0000000000002600. Ann Surg. 2019. PMID: 29227344
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.
Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS. Kamran SC, et al. Among authors: nipp rd. Cancer Med. 2018 Jul;7(7):2934-2942. doi: 10.1002/cam4.1558. Epub 2018 May 17. Cancer Med. 2018. PMID: 29771009 Free PMC article.
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Murphy JE, et al. Among authors: nipp rd. JAMA Oncol. 2019 Jul 1;5(7):1020-1027. doi: 10.1001/jamaoncol.2019.0892. JAMA Oncol. 2019. PMID: 31145418 Free PMC article. Clinical Trial.
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.
Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB. Parikh AR, et al. Among authors: nipp rd. Nat Med. 2019 Sep;25(9):1415-1421. doi: 10.1038/s41591-019-0561-9. Epub 2019 Sep 9. Nat Med. 2019. PMID: 31501609 Free PMC article.
179 results